1 SARS-CoV-2 Omicron subvariants Spike recognition and neutralization elicited after the

2 third dose of mRNA vaccine

Alexandra Tauzin^{1,2}, Alexandre Nicolas^{1,2,10}, Shilei Ding^{1,10}, Mehdi Benlarbi^{1,2}, Halima Medjahed¹, 3 Debashree Chatterjee¹, Katrina Dionne^{1,2}, Shang Yu Gong^{1,3}, Gabrielle Gendron-Lepage¹, Yuxia 4 5 Bo⁴, Josée Perreault⁵, Guillaume Goyette¹, Laurie Gokool¹, Pascale Arlotto¹, Chantal

- Morrisseau¹, Cécile Tremblay^{1,2}, Valérie Martel-Laferrière^{1,2}, Gaston De Serres⁶, Inès Levade⁷, 6
- 7 Daniel E. Kaufmann^{1,8,9}, Marceline Côté⁴, Renée Bazin⁵ and Andrés Finzi^{1,2,3,11,*}
- 8
- 9 ¹Centre de Recherche du CHUM, Montreal, QC, H2X 0A9 Canada
- 10 ²Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, QC, H2X 11 0A9, Canada
- 12 ³Department of Microbiology and Immunology, McGill University, Montreal, QC H3A 2B4, Canada
- 13 ⁴Department of Biochemistry, Microbiology and Immunology, and Centre for Infection, Immunity, and
- 14 Inflammation, University of Ottawa, Ottawa, ON K1H 8M5, Canada
- 15 ⁵Héma-Québec, Affaires Médicales et Innovation, Quebec, QC G1V 5C3, Canada
- 16 ⁶Institut National de Santé Publique du Québec, Quebec, QC, H2P 1E2, Canada
- 17 ⁷Laboratoire de Santé Publique du Québec, Institut National de Santé Publique du Québec, Sainte-Anne-18 de-Bellevue, QC H9X 3R5, Canada.
- 19 ⁸Département de Médecine, Université de Montréal, Montreal, QC, H3T 1J4, Canada
- 20 ⁹Division of Infectious Diseases, Department of Medicine, University Hospital of Lausanne and University 21
- of Lausanne, Lausanne, CH-1011, Switzerland
- 22
- 23 ¹⁰These authors contributed equally
- 24 ¹¹Lead contact
- 25 *Correspondence: andres.finzi@umontreal.ca (A.F.)

28 SUMMARY

29 Several SARS-CoV-2 Omicron subvariants have recently emerged, becoming the 30 dominant circulating strains in many countries. These variants contain a large number of 31 mutations in their Spike glycoprotein, raising concerns about vaccine efficacy. In this study, we 32 evaluate the ability of plasma from a cohort of individuals that received three doses of mRNA 33 vaccine to recognize and neutralize these Omicron subvariant Spikes. We observed that BA.4/5 34 and BQ.1.1 Spikes are markedly less recognized and neutralized compared to the D614G and 35 the other Omicron subvariant Spikes tested. Also, individuals who have been infected before or 36 after vaccination present better humoral responses than SARS-CoV-2 naïve vaccinated 37 individuals, thus indicating that hybrid immunity generates better humoral responses against 38 these subvariants.

39

Keywords: Coronavirus, COVID-19, SARS-CoV-2, Third mRNA vaccine dose, Spike
glycoproteins, B cell responses, Humoral responses, Neutralization, Omicron subvariants, hybrid
immunity

43 INTRODUCTION

The SARS-CoV-2 Omicron variant BA.1 emerged at the end of 2021 and rapidly became the dominant circulating strain in the world ^{1,2}. Since its emergence, several sublineages of Omicron rapidly replaced the BA.1 variant due to higher transmission rates. BA.2 became the dominant circulating strain in spring 2022 ^{3,4}, and currently the BA.4 and BA.5 variants [sharing the same mutations in their Spike (S) glycoproteins, named BA.4/5 S in the manuscript], are the dominant circulating strains in several countries ^{5–8}. BA.2.75, BA.4.6 and BQ.1.1 have emerged more recently and are spreading worldwide ^{9,10}.

51 It was previously shown that poor humoral responses against BA.1 and BA.2 variants were 52 observed after two doses of mRNA vaccine ^{11–13}. We and other reported that an extended interval 53 between the first two doses of mRNA vaccine led to strong humoral responses to several variants 54 of concern (VOCs) including BA.1 and BA.2 after the second dose of mRNA vaccine ^{14–16}. However, a third dose of mRNA vaccine led to an increase of humoral responses against these 55 56 Omicron variants, regardless of the interval between doses ^{11,13,16,17}. Previous studies also 57 reported that breakthrough infection (BTI) in vaccinated people induced strong neutralizing Abs 58 against VOCs, including BA.1^{18,19}. However, recent studies have shown that BA.4/5, BA.2.75, BA.4.6 and BQ.1.1 appear to be more resistant than BA.1 and BA.2 to vaccination and 59 monoclonal antibodies (Abs) ²⁰⁻²⁶. 60

In this study, we analyzed the ability of plasma from vaccinated individuals to recognize and neutralize pseudoviral particles bearing different Omicron subvariant Spikes four weeks (median [range]: 30 days [20–44 days]) and four months (median [range]: 121 days [92–135 days]) after the third dose of mRNA vaccine. This study was conducted in a cohort of individuals who received their first two doses with a 16-weeks extended interval (median [range]: 110 days [54– 146 days]) and their third dose seven months after the second dose (median [range]: 211 days [151-235 days]). The cohort included 15 naïve individuals who were never infected with SARS-

CoV-2, 15 previously infected (PI) individuals who were infected during the first wave of COVID-19 in early 2020 (before the advent of the alpha variant and other VOCs) and before vaccination, and 15 BTI individuals who were infected after vaccination. All BTI individuals were infected between mid-December 2021 and May 2022, when almost only Omicron variants (BA.1 and BA.2) were circulating in Quebec. Basic demographic characteristics of the cohorts and detailed vaccination time points are summarized in Table 1 and Figure 1A.

74

75 **RESULTS**

76 **RBD-specific IgG and associated avidity.**

77 We first measured the level of anti-RBD IgG four weeks and four months after the third dose of mRNA vaccine in naïve, BTI and PI individuals (Figure 1A) by a well described ELISA 78 79 assav ^{16,27–30} (Figure 1B). Four weeks after the third dose, we did not observe significant 80 differences in the level of IgG between the three groups. Four months after the third dose, we 81 observed that the level of IgG significantly decreased in all groups, but to a higher extent in naïve 82 individuals. No significant differences were observed between naïve, BTI and PI individuals four 83 months after the boost. We also measured the avidity of anti-RBD IgG induced after the third dose of mRNA vaccine using a previously described assay ^{28,31}. Four weeks after the third dose, we 84 85 observed that naïve donors had IgG with lower avidity, although we only measured significant 86 difference with BTI individuals (Figure 1C). Four months after the third dose, the avidity of these 87 IgG slightly decreased for naïve individuals but remained stable for BTI and PI groups.

88

89 **RBD-specific B cell responses after the third dose of mRNA vaccine.**

We also monitored the SARS-CoV-2-specific B cells (identified as CD19+ CD20+) by flow
 cytometry, using two recombinant RBD protein probes labeled with two different fluorochromes

92 (Alexa Fluor 594 and Alexa Fluor 488) (Figure S1A) ^{30,32}. Four weeks after the third dose of mRNA
93 vaccine, no significant differences in the level of circulating B cells were observed between the
94 three groups (Figure 1D). Four months after the boost, this level significantly decreased for naïve
95 donors but not for individuals with hybrid immunity (PI and BTI). For BTI individuals, we observed
96 an increase, with some donors presenting a higher level of circulating RBD-specific B cells,
97 probably due to recent infection.

98

99 Recognition of SARS-CoV-2 Spike variants by plasma from vaccinated individuals.

100 We next measured the ability of plasma to recognize the SARS-CoV-2 D614G and different 101 Omicron subvariants S in vaccinated naïve, PI and BTI individuals four weeks and four months 102 after the third dose of mRNA vaccine. Spike expression levels of the Spike variants were 103 normalized to the signal obtained with the conformationally independent anti-S2 neutralizing CV3-104 25 antibody ^{33–35} that efficiently recognized all these Spikes despite their various mutations (Figure 105 S1B, S2A-C). Four weeks after the third dose of mRNA vaccine, we observed that plasma from 106 PI individuals recognized more efficiently the D614G S than naïve individuals (Figure 2A). We 107 also observed that BTI individuals recognized the D614G S as efficiently as the PI individuals. 108 Four months after the third dose, the level of recognition of the D614G S decreased for the three 109 groups but with a more significant reduction in the naïve group. For the BA.2, BA.4/5 and BQ.1.1 110 S, naïve and BTI had the same level of recognition four weeks after the third dose, and this level 111 was significantly lower than for PI individuals (Figure 2B-C, F). For BA.2.75 and BA.4.6 S, we only 112 observed significant differences between naïve and PI individuals four weeks after the third dose 113 (Figure 2D-E). Four months after the third dose, we observed a significant decrease of the 114 recognition for naïve and PI individuals, with the exception of the BQ.1.1 S for which the level 115 remained stable in the PI group (Figure 2A-F). For the BTI group, the level of recognition remained 116 more stable and reached the same level than for the PI group for all tested Spikes. We also

117	observed that the BA.4/5 and the BQ.1.1 S were always less recognized than the D614G and
118	other Omicron subvariants S at both time points for all groups (Figure 2G-H).

119

120 Neutralizing activity of the vaccine-elicited antibodies.

121 We also evaluated the neutralizing activity against pseudoviral particles bearing these 122 Spikes in the three groups. Of note, all Spikes were incorporated into pseudoviral particles to 123 similar extents (Figure S2C) and had similar levels of infectivity in our assay (Figure S2D). In 124 agreement with the pattern of S recognition, PI individuals neutralized more efficiently all the S 125 variants tested than naïve individuals four weeks after the third dose (Figure 3A-F). For the BTI 126 group, the level of neutralizing Abs was intermediate between the two other groups. Four months 127 after the third dose, we did not observe significant differences between PI and BTI individuals. In 128 contrast, the naïve group neutralized less efficiently the D614G, and Omicron subvariants S 129 (Figure 3A-F). Four weeks after the third dose, no significant difference in the level of 130 neutralization was measured between the D614G and BA.2 S for the three groups (Figure 2G). 131 In contrast, the other Omicron variants S were more resistant to neutralization than the D614G S 132 in all groups. Four months after the third dose, weak or no neutralizing activity against Omicron 133 subvariants S was detected in most naïve individuals (Figure 3B-F, H). For BTI and PI individuals, 134 although neutralizing activity was higher than in naïve individuals, the BA.4/5, BA.2.75, BA.4.6 135 and BQ.1.1 S were also significantly less neutralized than the D614G and, in some instances, 136 BA.2 S (Figure 3B-F, H).

138 **DISCUSSION**

More than two years after its emergence, and although an important proportion of the world population has received several doses of vaccine, the SARS-CoV-2 variants continue to circulate globally. In recent months, new sub-variants of Omicron emerged, carrying increasing numbers of mutations making them more transmissible and resistant to vaccination and monoclonal antibodies treatment ^{8,17,20–22,25}. In agreement with this, we observed that the BA.4/5, BA.2.75, BA.4.6 and BQ.1.1 S were less efficiently recognized and neutralized than the D614G and the BA.2 S by plasma from individuals who received three doses of mRNA vaccine.

Several studies reported that poor neutralizing activity against VOCs was observed after two doses of mRNA vaccine, but a third dose strongly improved this response ^{11,16,36}. However, when the second dose of vaccine was administered with an extended 16-weeks interval, higher humoral responses against VOCs (including BA.1 and BA.2) were observed after the second dose of vaccine ¹⁴, that were not increased by a booster dose ¹⁶. Therefore, there is no evidence that additional doses of the original SARS-CoV-2 vaccines after the third dose will result in increased responses against VOCs.

The Omicron variants spread more easily in vaccinated individuals than pre-Omicron variants ^{37,38}. Interestingly, it was recently shown that previous infection with an Omicron variant prevents reinfection more efficiently than previous infection with a pre-Omicron variant ^{39,40}, thus suggesting that new vaccines based on Omicron variants may generate humoral responses more likely to control Omicron sub-variants.

158 It was previously shown that hybrid immunity due to SARS-CoV-2 infection followed by 159 vaccination confers stronger immune responses than vaccination alone ^{16,32,40,41}. Accordingly, 160 here we observed that individuals with BTI had the same level of S recognition and neutralization 161 than individuals previously infected supporting the concept that hybrid protection is similar

whatever the order of infection and vaccination. However, the durability of these responsesremains unknown.

164 In conclusion, virus recognition and neutralizing activity induced by current mRNA vaccine 165 are low against Omicron subvariants, rapidly decline over 4 months in naïve individuals, and will 166 likely decrease further with future SARS-CoV-2 evolution. There is a need to rapidly develop new 167 generations of vaccines that will elicit broader and less labile protection.

168

169 LIMITATIONS OF THE STUDY

170 One of the limitations of the study is that for most BTI individuals, we do not have the exact 171 day of infection and by which variant. We can only confirm whether they were infected before the 172 first timepoint studied or between the 2 timepoints. Furthermore, it is very likely that some PI 173 individuals were exposed a second time. However, in our study, no case of infection was 174 confirmed by PCR in PI group, and since they were already infected a first time, we cannot 175 conclude that a positive anti-N corresponds to a new infection or to the first. Finally, while we did 176 not observe major differences in infectivity with our pseudoviral particles, it is possible that 177 differences in infectivity and replication exist when using authentic live viruses. For this reason 178 we only report on plasma neutralization profiles, which were shown to be similar between 179 pseudoviral particles and authentic viruses and have been largely used by the field to inform on 180 neutralizing responses elicited by natural infection and vaccination ⁴²⁻⁴⁶.

181 ACKNOWLEDGMENTS

The authors are grateful to the individuals who participated in this study. The authors thank the CRCHUM BSL3 and Flow Cytometry Platforms for technical assistance. This work was supported by le Ministère de l'Économie et de l'Innovation du Québec, Programme de soutien aux organismes de recherche et d'innovation to A.F. and by the Fondation du CHUM. This work

186 was also supported by a CIHR foundation grant #352417, by a CIHR operating Pandemic and Health Emergencies Research grant #177958, by an Exceptional Fund COVID-19 from the 187 188 Canada Foundation for Innovation (CFI) #41027 to A.F. and by a FRQS Merit Research Scholar 189 award (# 268471) to D.E.K. Work on variants presented was also supported by the Sentinelle 190 COVID Quebec network led by the LSPQ in collaboration with Fonds de Recherche du Québec 191 Santé (FRQS) to A.F. This work was also partially supported by a CIHR COVID-19 rapid response 192 grant (OV3 170632) and CIHR stream 1 SARS-CoV-2 Variant Research to M.C. A.F. is the 193 recipient of Canada Research Chair on Retroviral Entry no. RCHS0235 950-232424. M.C is a 194 Tier II Canada Research Chair in Molecular Virology and Antiviral Therapeutics (950-232840). 195 C.T. is the Pfizer/Université de Montréal Chair on HIV translational research. A.T. was supported 196 by MITACS Accélération postdoctoral fellowship. M.B. was the recipient of a CIHR master's 197 scholarship award. The funders had no role in study design, data collection and analysis, decision 198 to publish, or preparation of the manuscript. We declare no competing interests.

199

200 AUTHOR CONTRIBUTIONS

A.T. and A.F. conceived the study. A.T., A.N., S.D., D.C., M.B., K.D., S.Y.G., G.G.L., H.M.,
G.G., J.P., Y.B., and A.F. performed, analyzed, and interpreted the experiments. A.T. performed
statistical analysis. G.G.L., H.M., G.G., M.C., and A.F. contributed unique reagents. L.G., P.A.,
C.M., C.T., and V.M.-L. collected and provided clinical samples. R.B., G.D.S., D.E.K. and I.L.
provided scientific input related to VOCs and vaccine efficacy. A.T. and A.F. wrote the manuscript
with inputs from others. Every author has read, edited, and approved the final manuscript.

207

208 DECLARATION OF INTERESTS

209 The authors declare no conflict of interest.

210 FIGURE LEGENDS

Figure 1. Anti-RBD IgG level, associated anti-RBD avidity and RBD-Specific B cell responses in plasma from naïve, BTI and PI individuals after the third dose of mRNA vaccine.

214 (A) SARS-CoV-2 vaccine cohort design. The vellow box represents the period under study. (B-215 C) Indirect ELISAs were performed by incubating plasma samples from naïve. BTI or PI 216 individuals collected 4 weeks or 4 months after the third dose of mRNA vaccine with recombinant 217 SARS-CoV-2 RBD protein. Anti-RBD Ab binding was detected using HRP-conjugated anti-human 218 IgG. (B) RLU values obtained were normalized to the signal obtained with the anti-RBD CR3022 219 mAb present in each plate. (C) The RBD avidity index corresponded to the value obtained with 220 the stringent (8M urea) ELISA divided by that obtained without urea. (D) The frequencies of RBD+ 221 B cells were measured by flow cytometry. (**B-D**) Plasma samples were grouped in two different 222 time points (4 weeks and 4 months). Naïve, BTI and PI individuals are represented by red, vellow 223 and black points respectively, undetectable measures are represented as white symbols, and limits of detection are plotted. Error bars indicate means ± SEM. (* P < 0.05; ** P < 0.01; *** P < 224 225 0.001; **** P < 0.0001; ns, non-significant). For all groups, n=15 (**B-C**) or n=10 (**D**).

226

Figure 2. Recognition of SARS-CoV-2 Spike variants by plasma from naïve, BTI and PI individuals after the third dose of mRNA vaccine.

(A-G) 293T cells were transfected with the indicated full-length S from different SARS-CoV-2 variants and stained with the CV3-25 mAb or with plasma from naïve, BTI or PI individuals collected 4 weeks or 4 months after the third dose of mRNA vaccine and analyzed by flow cytometry. The values represent the MFI normalized by CV3-25 Ab binding. (A-F) Plasma samples were grouped in two different time points (4 weeks and 4 months). (G-H) Binding of

plasma collected at 4 weeks (**G**) and 4 months (**H**) post vaccination were measured. Naïve, BTI and PI individuals are represented by red, yellow and black points respectively, undetectable measures are represented as white symbols, and limits of detection are plotted. Error bars indicate means \pm SEM. (* P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001; ns, non-significant). For all groups, n=15.

239

Figure 3. Neutralization activity of SARS-CoV-2 Spike variants by plasma from naïve, BTI and PI individuals after the third dose of mRNA vaccine.

242 (A-G) Neutralization activity was measured by incubating pseudoviruses bearing SARS-CoV-2 S 243 glycoproteins, with serial dilutions of plasma for 1 h at 37°C before infecting 293T-ACE2 cells. 244 Neutralization half maximal inhibitory serum dilution (ID_{50}) values were determined using a 245 normalized non-linear regression using GraphPad Prism software. (A-F) Plasma samples were 246 arouped in two different time points (4 weeks and 4 months). (G-H) Neutralization activity of 247 plasma collected at 4 weeks (G) and 4 months (H) post vaccination were measured. Naïve, BTI 248 and PI individuals are represented by red, yellow and black points respectively, undetectable 249 measures are represented as white symbols, and limits of detection are plotted. Error bars 250 indicate means ± SEM. (* P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001; ns, non-significant). 251 For all groups, n=15.

252

254

255 Table 1. Characteristics of the vaccinated SARS-CoV-2 cohorts

		Entire cohort	Naïve	Breakthrough infection ^b	Previously infected
Number		45	15	15	15
Age		51 (24-67)	54 (24-67)	43 (30-64)	48 (29-65)
Gender	Male (n)	17	4	5	8
	Female (n)	28	11	10	7
	1 st dose	Pfz=43 ; M=1 ; AZ=1	Pfz=14 ; M=1	Pfz=14 ; AZ=1	Pfz=15
Vaccine	2 nd dose	Pfz=43 ; M=1 ; AZ=1	Pfz=14 ; M=1	Pfz=14 ; AZ=1	Pfz=15
	3 rd dose	Pfz=40 ; M=5	Pfz=15	Pfz=14 ; AZ=1	Pfz=11 ; AZ=4
Days between symptom onset and the 1 st dose ^a		N/A	N/A	N/A	288 (166-321)
Days between the 1 st and 2 nd dose ^a		110 (54-146)	109 (65-120)	110 (54-113)	112 (90-146)
Days between the 2 nd and 3 rd dose ^a		211 (151-235)	210 (184-227)	215 (151-224)	219 (187-235)
Days between the 3 rd dose and 4W		30 (20-44)	32 (21-37)	28 (20-38)	33 (24-44)
Days between the 3 rd dose and 4M		121 (92-135)	124 (105-135)	121 (92-131)	119 (111-127)

^a Values displayed are medians, with ranges in parentheses. Continuous variables were compared by using KruskalWallis tests. p<0.05 was considered statistically significant for all analyses. No statistical differences were found for
any of the parameter tested between the different groups. Pfz= Pfizer/BioNtech BNT162b2, M= Moderna mRNA-1273,
AZ= AstraZeneca ChAdOx1. ^b All Breakthrough infection individuals were infected between mid-December 2021 and
May 2022, when almost only Omicron variants (BA.1 and BA.2) were circulating in Quebec. 6 BTI individuals were
infected before the time point collected 4 weeks after the third dose and 9 BTI individuals were infected between the
two time points.

265	STAR METHODS					
266						
267	RESOURCE AVAILABILITY					
268						
269	Lead contact					
270	Further information and requests for resources and reagents should be directed to and will be					
271	fulfilled by the lead contact, Andrés Finzi (andres.finzi@umontreal.ca).					
272						
273	Materials availability					
274	All unique reagents generated during this study are available from the Lead contact withou					
275	restriction.					
276						
277	Data and code availability					
278	 All data reported in this paper will be shared by the lead contact 					
279	(andres.finzi@umontreal.ca) upon request.					
280	This paper does not report original code.					
281	Any additional information required to reanalyze the data reported in this paper is available					
282	from the lead contact (andres.finzi@umontreal.ca) upon request.					
283						
284	EXPERIMENTAL MODEL AND SUBJECT DETAILS					
285						
286	Ethics Statement					
287	All work was conducted in accordance with the Declaration of Helsinki in terms of informed					
288	consent and approval by an appropriate institutional board. Blood samples were obtained from					
289	donors who consented to participate in this research project at CHUM (19.381). Plasmas and					

PBMCs were isolated by centrifugation and Ficoll gradient, and samples stored at -80°C and in
liquid nitrogen respectively, until use.

292

293 Human subjects

294 The study was conducted in 15 SARS-CoV-2 naïve individuals (4 males and 11 females; age 295 range: 24-67 years), 15 SARS-CoV-2 breakthrough infection individuals (5 males and 10 females; 296 age range: 30-64 years) infected after the second or third dose of mRNA vaccine (6 BTI were 297 infected before the time point collected 4 weeks after the third dose and 9 individuals were infected 298 between the two time points), and 15 SARS-CoV-2 previously infected individuals (8 males and 299 7 females; age range: 29-65 years) infected before vaccination during the first wave of COVID-300 19 in march-may 2020. This information is presented in table 1. No specific criteria such as 301 number of patients (sample size), gender, clinical or demographic were used for inclusion, beyond 302 PCR confirmed SARS-CoV-2 infection in adults before vaccination for PI group, PCR confirmed 303 SARS-CoV-2 infection or anti-N positive in adults after vaccination for BTI group and no detection 304 of Abs recognizing the N protein for naïve individuals.

305

306 Plasma and antibodies

307 Plasmas were isolated by centrifugation with Ficoll gradient, heat-inactivated for 1 hour at 56°C 308 and stored at -80°C until use in subsequent experiments. Healthy donor's plasmas, collected 309 before the pandemic, were used as negative controls, and used to calculate the seropositivity 310 threshold in our ELISAs and flow cytometry assays (data not shown). The RBD-specific 311 monoclonal antibody CR3022 was used as a positive control in ELISA assays, and the 312 conformationally independent S2-specific monoclonal antibody CV3-25 was used as a positive 313 control and to normalize Spike expression in our flow cytometry assays, as described ^{34,47-49}. 314 Horseradish peroxidase (HRP)-conjugated Abs able to detect the Fc region of human IgG

(Invitrogen) was used as secondary Abs to detect Ab binding in ELISA experiments. Alexa Fluor647-conjugated goat anti-human Abs able to detect all Ig isotypes (anti-human IgM+IgG+IgA;
Jackson ImmunoResearch Laboratories) were used as secondary Abs to detect plasma binding
in flow cytometry experiments.

319

320 Cell lines

321 293T human embryonic kidney cells (obtained from ATCC) and Cf2.Th cells (a kind gift from 322 Joseph Sodroski, Dana Farber Cancer Institute (DFCI), Boston, MA, USA) were maintained at 323 37°C under 5% CO₂ in Dulbecco's modified Eagle's medium (DMEM) (Wisent) containing 5% fetal 324 bovine serum (FBS) (VWR) and 100 μ g/ml of penicillin-streptomycin (Wisent). 293T-ACE2 cell 325 line was previously reported ²⁹.

326

327 METHOD DETAILS

328 Plasmids

The plasmids encoding the SARS-CoV-2 Spike variants were previously described ^{16,48,50}. The plasmids encoding the BA.4/5, BA.2.75, BA.4.6 and BQ.1.1 Spike was generated by overlapping PCR using the BA.2 SARS-CoV-2 Spike gene as a template and cloned in pCAGGS. All constructs were verified by Sanger sequencing. Spike variant sequences are outlined in Figure S2A. The pNL4.3 R-E- Luc was obtained from the NIH AIDS Reagent Program. The vesicular stomatitis virus G (VSV-G)-encoding plasmid (pSVCMV-IN-VSV-G) was previously described ²⁹.

335

336 **Protein expression and purification**

FreeStyle 293F cells (Invitrogen) were grown in FreeStyle 293F medium (Invitrogen) to a density of 1×10⁶ cells/mL at 37°C with 8% CO₂ with regular agitation (150 rpm). Cells were transfected with a plasmid coding for SARS-CoV-2 S WT RBD ⁵⁰ using ExpiFectamine 293 transfection reagent, as directed by the manufacturer (Invitrogen). One week later, cells were pelleted and discarded. Supernatants were filtered using a 0.22 µm filter (Thermo Fisher Scientific). The recombinant RBD proteins were purified by nickel affinity columns, as directed by the manufacturer (Invitrogen). The RBD preparations were dialyzed against phosphate-buffered saline (PBS) and stored in aliquots at -80°C until further use. To assess purity, recombinant proteins were loaded on SDS-PAGE gels and stained with Coomassie Blue.

346

347 Enzyme-linked immunosorbent assay (ELISA) and RBD avidity index

348 The SARS-CoV-2 WT RBD ELISA assay used was previously described ^{29,50}. Briefly, recombinant 349 SARS-CoV-2 WT RBD proteins (2.5 mg/mL), or bovine serum albumin (BSA) (2.5 mg/mL) as a 350 negative control, were prepared in PBS and were adsorbed to plates (MaxiSorp Nunc) overnight 351 at 4°C. Coated wells were subsequently blocked with blocking buffer (Tris-buffered saline [TBS] 352 containing 0.1% Tween20 and 2% BSA) for 1h at room temperature. Wells were then washed 353 four times with washing buffer (Tris-buffered saline [TBS] containing 0.1% Tween20). CR3022 354 mAb (50 ng/mL) or a 1/500 dilution of plasma were prepared in a diluted solution of blocking buffer 355 (0.1% BSA) and incubated with the RBD-coated wells for 90 min at room temperature. Plates 356 were washed four times with washing buffer followed by incubation with secondary Abs (diluted 357 in a diluted solution of blocking buffer (0.4% BSA)) for 1h at room temperature, followed by four 358 washes. To calculate the RBD-avidity index, we performed in parallel a stringent ELISA, where 359 the plates were washed with a chaotropic agent, 8M of urea, added of the washing buffer. This 360 assay was previously described ³¹. HRP enzyme activity was determined after the addition of a 361 1:1 mix of Western Lightning oxidizing and luminol reagents (Perkin Elmer Life Sciences). Light 362 emission was measured with a LB942 TriStar luminometer (Berthold Technologies). Signal 363 obtained with BSA was subtracted for each plasma and was then normalized to the signal 364 obtained with CR3022 present in each plate. The seropositivity threshold was established using 365 the following formula: mean of pre-pandemic SARS-CoV-2 negative plasma + (3 standard 366 deviation of the mean of pre-pandemic SARS-CoV-2 negative plasma).

367

368 SARS-CoV-2-specific B cells characterization

369 To detect SARS-CoV-2-specific B cells, we conjugated recombinant RBD proteins with Alexa 370 Fluor 488 or Alexa Fluor 594 (Thermo Fisher Scientific) according to the manufacturer's protocol. 371 2×10⁶ frozen PBMCs from SARS-CoV-2 naïve, BTI and PI donors were prepared at a final 372 concentration of 4×10⁶ cells/mL in RPMI 1640 medium (GIBCO) supplemented with 10% of fetal 373 bovine serum (Seradigm), Penicillin/Streptomycin (GIBCO) and HEPES (GIBCO). After a rest of 374 2h at 37°C and 5% CO₂, cells were stained using Aquavivid viability marker (GIBCO) in DPBS 375 (GIBCO) at 4°C for 20 min. The detection of SARS-CoV-2-antigen specific B cells was done by 376 adding the RBD probes to the antibody cocktail listed in Table S1. Staining was performed at 4°C 377 for 30 min and cells were fixed using 2% paraformaldehyde at 4°C for 15 min. Stained PBMC 378 samples were acquired on Symphony cytometer (BD Biosciences) and analyzed using FlowJo 379 v10.8.0 software and the gating strategy presented in Figure S1A.

380

381

382 Cell surface staining and flow cytometry analysis

383 293T were transfected with full-length SARS-CoV-2 Spikes and a green fluorescent protein (GFP) 384 expressor (pIRES2-eGFP; Clontech) using the calcium-phosphate method. Two days post-385 transfection, Spike-expressing 293T cells were stained with the CV3-25 Ab (5 µg/mL) as control 386 or plasma from naïve, BTI or PI individuals (1:250 dilution) for 45 min at 37°C. AlexaFluor-647-387 conjugated goat anti-human IgG (1/1000 dilution) were used as secondary Abs. The percentage 388 of Spike-expressing cells (GFP + cells) was determined by gating the living cell population based 389 on viability dye staining (Aqua Vivid, Invitrogen). Samples were acquired on a LSR II cytometer 390 (BD Biosciences), and data analysis was performed using FlowJo v10.7.1 (Tree Star) using the 391 gating strategy presented in Figure S1B. The conformationally-independent anti-S2 antibody 392 CV3-25 was used to normalize Spike expression, as reported ^{33–35,48}. CV3-25 was shown to be

effective against all Spike variants (Figure S2B-C). The Median Fluorescence intensities (MFI)
obtained with plasma were normalized to the MFI obtained with CV3-25 and presented as
percentage of CV3-25 binding.

396

397 **Pseudoviral infectivity**

398 293T cells were transfected with the lentiviral vector pNL4.3 R-E- Luc (NIH AIDS Reagent 399 Program) and plasmid encoding for the indicated S glycoprotein (D614G, BA.2, BA.4/5, BA.2.75, 400 BA.4.6 or BQ.1.1) at a ratio of 10:1. Two days post-transfection, cell supernatants were harvested 401 and stored at -80°C until use. The RT activity was evaluated by measure of the incorporation of 402 [methyl-3H]TTP into cDNA of a poly(rA) template in the presence of virion-associated RT and 403 oligo(dT). Normalized amount of RT activity pseudoviral particles were added to 293T-ACE2 404 target cells for 48 h at 37°C. Then, cells were lysed by the addition of 30 µL of passive lysis buffer 405 (Promega) followed by one freeze-thaw cycle. An LB942 TriStar luminometer (Berthold 406 Technologies) was used to measure the luciferase activity of each well after the addition of 100 407 µL of luciferin buffer (15mM MgSO4, 15mM KPO4 [pH 7.8], 1mM ATP, and 1mM dithiothreitol) 408 and 50 µL of 1mM d-luciferin potassium salt (Thermo Fisher Scientific). RLU values obtained were 409 normalized to D614G.

410

411 Virus neutralization assay

To produce SARS-CoV-2 pseudoviruses, 293T cells were transfected with the lentiviral vector pNL4.3 R-E- Luc (NIH AIDS Reagent Program) and a plasmid encoding for the indicated S glycoprotein (D614G, BA.2, BA.4/5, BA.2.75, BA.4.6 or BQ.1.1) at a ratio of 10:1. Two days posttransfection, cell supernatants were harvested and stored at -80°C until use. For the neutralization assay, 293T-ACE2 target cells were seeded at a density of 1×10⁴ cells/well in 96well luminometer-compatible tissue culture plates (PerkinElmer) 24h before infection. Pseudoviral particles were incubated with several plasma dilutions (1/50; 1/250; 1/1250; 1/6250; 1/31250) for

1h at 37°C and were then added to the target cells followed by incubation for 48h at 37°C. Cells were lysed by the addition of 30 μ L of passive lysis buffer (Promega) followed by one freeze-thaw cycle. An LB942 TriStar luminometer (Berthold Technologies) was used to measure the luciferase activity of each well after the addition of 100 μ L of luciferin buffer (15mM MgSO₄, 15mM KH₂PO₄ [pH 7.8], 1mM ATP, and 1mM dithiothreitol) and 50 μ L of 1mM d-luciferin potassium salt (Prolume). The neutralization half-maximal inhibitory dilution (ID₅₀) represents the plasma dilution to inhibit 50% of the infection of 293T-ACE2 cells by pseudoviruses.

426

427 Virus Capture Assay

The assay was previously described ⁵¹. Briefly, pseudoviral particles were produced by 428 429 transfecting 2×10⁶ 293T cells with pNL4.3 R-E- Luc (3.5 µg), pSVCMV-IN-VSV-G (1 µg) and 430 plasmids encoding for SARS-CoV-2 Spike glycoproteins (3.5 µg) using the standard calcium 431 phosphate protocol. 48 hours later, virion-containing supernatants were collected. White 432 MaxiSorp ELISA plates (Thermo Fisher Scientific, Waltham, MA, USA.) were plated with the CV3-433 25 mAb at 0.05 µg per well overnight at 4°C. Unbound antibodies were removed by washing the 434 plates twice with PBS. Plates were subsequently blocked with 3% BSA in PBS for 1 h at room 435 temperature. After the washes, 200 µL of virus-containing supernatant was added to the wells. 436 Viral capture by the Ab was visualized by adding 1×10⁴ SARS-CoV-2-resistant Cf2Th cells in full 437 DMEM medium per well. Forty-eight hours post-infection, cells were lysed by the addition of 30 438 µL of passive lysis buffer (Promega, Madison, WI, USA.) and three freeze-thaw cycles. An LB941 439 TriStar luminometer (Berthold Technologies) was used to measure the luciferase activity of each 440 well after the addition of 100 µL of luciferin buffer (15 mM MgSO4, 15 mM KH2PO4 (pH 7.8), 1 441 mM ATP, and 1 mM dithiothreitol) and 50 µL of 1 mM D-luciferin potassium salt (Prolume, 442 Randolph, VT, USA.).

443

445 QUANTIFICATION AND STATISTICAL ANALYSIS

446 Statistical analysis

- 447 Symbols represent biologically independent samples from SARS-CoV-2 naïve, BTI or PI
- 448 individuals. Statistics were analyzed using GraphPad Prism version 8.0.1 (GraphPad, San Diego,
- 449 CA). Every dataset was tested for statistical normality and this information was used to apply the
- 450 appropriate (parametric or nonparametric) statistical test. p values < 0.05 were considered
- 451 significant; significance values are indicated as *P<0.05, **P<0.01, ***P<0.001, ***P<0.0001, ns,
- 452 non-significant.

454 SUPPLEMENTAL INFORMATION

455 Supplemental information can be found online at ...

456 **REFERENCES**

- Viana, R., Moyo, S., Amoako, D.G., Tegally, H., Scheepers, C., Althaus, C.L., Anyaneji, U.J.,
 Bester, P.A., Boni, M.F., Chand, M., et al. (2022). Rapid epidemic expansion of the SARS CoV-2 Omicron variant in southern Africa. Nature, 1–10. 10.1038/s41586-022-04411-y.
- 460 2. WHO Update on Omicron, https://www.who.int/news/item/28-11-2021-update-on-omicron.
 461 https://www.who.int/news/item/28-11-2021-update-on-omicron.
- CDC (2022). COVID Data Tracker Weekly Review, https://www.cdc.gov/coronavirus/2019ncov/covid-data/covidview/past-reports/04222022.html. Cent. Dis. Control Prev. https://www.cdc.gov/coronavirus/2019-ncov/covid-data/covidview/pastreports/04222022.html.
- 466
 4. Elliott, P., Eales, O., Steyn, N., Tang, D., Bodinier, B., Wang, H., Elliott, J., Whitaker, M.,
 467
 468
 468
 468
 468
 469
 469
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460</
- Mohapatra, R.K., Kandi, V., Sarangi, A.K., Verma, S., Tuli, H.S., Chakraborty, S.,
 Chakraborty, C., and Dhama, K. (2022). The recently emerged BA.4 and BA.5 lineages of
 Omicron and their global health concerns amid the ongoing wave of COVID-19 pandemic –
 Correspondence. Int. J. Surg. Lond. Engl. *103*, 106698. 10.1016/j.ijsu.2022.106698.
- 6. PHO (2022). Public Health Ontario : SARS-CoV-2 Omicron Variant Sub-Lineages BA.4 and BA.5: Evidence and Risk Assessment, chromeextension://efaidnbmnnnibpcajpcglclefindmkaj/https://www.publichealthontario.ca//media/Documents/nCoV/voc/2022/07/evidence-brief-ba4-ba5-risk-assessment-jul-8.pdf?sc_lang=en.
- Tegally, H., Moir, M., Everatt, J., Giovanetti, M., Scheepers, C., Wilkinson, E., Subramoney,
 K., Makatini, Z., Moyo, S., Amoako, D.G., et al. (2022). Emergence of SARS-CoV-2 Omicron
 lineages BA.4 and BA.5 in South Africa. Nat. Med., 1–1. 10.1038/s41591-022-01911-2.
- 481 8. Yamasoba, D., Kosugi, Y., Kimura, I., Fujita, S., Uriu, K., Ito, J., and Sato, K. (2022).
 482 Neutralisation sensitivity of SARS-CoV-2 omicron subvariants to therapeutic monoclonal 483 antibodies. Lancet Infect. Dis. *22*, 942–943. 10.1016/S1473-3099(22)00365-6.
- WHO (2022). Tracking SARS-CoV-2 variants, https://www.who.int/en/activities/tracking SARS-CoV-2-variants/. https://www.who.int/health-topics/typhoid/tracking-SARS-CoV-2 variants.
- 487 10. IDSA (2022). SARS-CoV-2 Variants, https://www.idsociety.org/covid-19-real-time-learning-488 network/emerging-variants/emerging-covid-19-variants/. https://www.idsociety.org/covid-19-489 real-time-learning-network/emerging-variants/emerging-covid-19-variants/.
- 490 11. Muik, A., Lui, B.G., Wallisch, A.-K., Bacher, M., Mühl, J., Reinholz, J., Ozhelvaci, O.,
 491 Beckmann, N., Güimil Garcia, R. de la C., Poran, A., et al. (2022). Neutralization of SARS492 CoV-2 Omicron by BNT162b2 mRNA vaccine–elicited human sera. Science *375*, 678–680.
 493 10.1126/science.abn7591.

- 12. Nemet, I., Kliker, L., Lustig, Y., Zuckerman, N., Erster, O., Cohen, C., Kreiss, Y., Alroy-Preis,
 S., Regev-Yochay, G., Mendelson, E., et al. (2022). Third BNT162b2 Vaccination
 Neutralization of SARS-CoV-2 Omicron Infection. N. Engl. J. Med. *386*, 492–494.
 10.1056/NEJMc2119358.
- 498 13. Yu, J., Collier, A.Y., Rowe, M., Mardas, F., Ventura, J.D., Wan, H., Miller, J., Powers, O.,
 499 Chung, B., Siamatu, M., et al. (2022). Neutralization of the SARS-CoV-2 Omicron BA.1 and
 500 BA.2 Variants. N. Engl. J. Med. *386*, 1579–1580. 10.1056/NEJMc2201849.
- 14. Chatterjee, D., Tauzin, A., Marchitto, L., Gong, S.Y., Boutin, M., Bourassa, C., BeaudoinBussières, G., Bo, Y., Ding, S., Laumaea, A., et al. (2022). SARS-CoV-2 Omicron Spike
 recognition by plasma from individuals receiving BNT162b2 mRNA vaccination with a 16week interval between doses. Cell Rep., 110429. 10.1016/j.celrep.2022.110429.
- 505 15. Payne, R.P., Longet, S., Austin, J.A., Skelly, D.T., Dejnirattisai, W., Adele, S., Meardon, N., 506 Faustini, S., Al-Taei, S., Moore, S.C., et al. (2021). Immunogenicity of standard and extended 507 dosing intervals of BNT162b2 mRNA vaccine. Cell 184, 5699-5714.e11. 508 10.1016/j.cell.2021.10.011.
- 509 16. Tauzin, A., Gong, S.Y., Chatterjee, D., Ding, S., Painter, M.M., Goel, R.R., Beaudoin510 Bussières, G., Marchitto, L., Boutin, M., Laumaea, A., et al. (2022). A boost with SARS-CoV511 2 BNT162b2 mRNA vaccine elicits strong humoral responses independently of the interval
 512 between the first two doses. Cell Rep. *41*. 10.1016/j.celrep.2022.111554.
- 513 17. Kurhade, C., Zou, J., Xia, H., Cai, H., Yang, Q., Cutler, M., Cooper, D., Muik, A., Jansen, K.U.,
 514 Xie, X., et al. (2022). Neutralization of Omicron BA.1, BA.2, and BA.3 SARS-CoV-2 by 3 doses
 515 of BNT162b2 vaccine. Nat. Commun. *13*, 3602. 10.1038/s41467-022-30681-1.
- 516 18. Kitchin, D., Richardson, S.I., van der Mescht, M.A., Motlou, T., Mzindle, N., Moyo-Gwete, T., 517 Makhado, Z., Ayres, F., Manamela, N.P., Spencer, H., et al. (2022). Ad26.COV2.S 518 breakthrough infections induce high titers of neutralizing antibodies against Omicron and 519 other SARS-CoV-2 variants of concern. Cell Rep. Med. 3. 100535. 520 10.1016/j.xcrm.2022.100535.
- 19. Miyamoto, S., Arashiro, T., Adachi, Y., Moriyama, S., Kinoshita, H., Kanno, T., Saito, S.,
 Katano, H., Iida, S., Ainai, A., et al. (2022). Vaccination-infection interval determines crossneutralization potency to SARS-CoV-2 Omicron after breakthrough infection by other variants.
 Med, S2666634022000897. 10.1016/j.medj.2022.02.006.
- 525 20. Qu, P., Faraone, J., Evans, J.P., Zou, X., Zheng, Y.-M., Carlin, C., Bednash, J.S., Lozanski, 526 G., Mallampalli, R.K., Saif, L.J., et al. (2022). Neutralization of the SARS-CoV-2 Omicron BA.4/5 527 and BA.2.12.1 Subvariants. Ν. Engl. J. Med. 386. 2526-2528. 528 10.1056/NEJMc2206725.
- 529 21. Tuekprakhon, A., Nutalai, R., Dijokaite-Guraliuc, A., Zhou, D., Ginn, H.M., Selvaraj, M., Liu,
 530 C., Mentzer, A.J., Supasa, P., Duyvesteyn, H.M.E., et al. (2022). Antibody escape of SARS531 CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum. Cell *185*, 2422-2433.e13.
 532 10.1016/j.cell.2022.06.005.

- 533 22. Wang, Q., Guo, Y., Iketani, S., Nair, M.S., Li, Z., Mohri, H., Wang, M., Yu, J., Bowen, A.D.,
 534 Chang, J.Y., et al. (2022). Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1,
 535 BA.4, & BA.5. Nature, 1–3. 10.1038/s41586-022-05053-w.
- Shen, X., Chalkias, S., Feng, J., Chen, X., Zhou, H., Marshall, J.-C., Girard, B., Tomassini,
 J.E., Aunins, A., Das, R., et al. (2022). Neutralization of SARS-CoV-2 Omicron BA.2.75 after
 mRNA-1273 Vaccination. N. Engl. J. Med. 387, 1234–1236. 10.1056/NEJMc2210648.
- 539 24. Sheward, D.J., Kim, C., Fischbach, J., Sato, K., Muschiol, S., Ehling, R.A., Björkström, N.K.,
 540 Hedestam, G.B.K., Reddy, S.T., Albert, J., et al. (2022). Omicron sublineage BA.2.75.2
 541 exhibits extensive escape from neutralising antibodies. Lancet Infect. Dis. *0*. 10.1016/S1473542 3099(22)00663-6.
- 543 25. Arora, P., Kempf, A., Nehlmeier, I., Schulz, S.R., Jäck, H.-M., Pöhlmann, S., and Hoffmann,
 544 M. (2022). Omicron sublineage BQ.1.1 resistance to monoclonal antibodies. Lancet Infect.
 545 Dis. 0. 10.1016/S1473-3099(22)00733-2.
- 546 26. Kurhade, C., Zou, J., Xia, H., Liu, M., Chang, H.C., Ren, P., Xie, X., and Shi, P.-Y. (2022).
 547 Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1, and XBB.1 by 4 doses of
 548 parental mRNA vaccine or a BA.5-bivalent booster. 2022.10.31.514580.
 549 10.1101/2022.10.31.514580.
- Tauzin, A., Nayrac, M., Benlarbi, M., Gong, S.Y., Gasser, R., Beaudoin-Bussières, G.,
 Brassard, N., Laumaea, A., Vézina, D., Prévost, J., et al. (2021). A single dose of the SARSCoV-2 vaccine BNT162b2 elicits Fc-mediated antibody effector functions and T cell
 responses. Cell Host Microbe 0. 10.1016/j.chom.2021.06.001.
- 554 28. Tauzin, A., Gong, S.Y., Beaudoin-Bussières, G., Vézina, D., Gasser, R., Nault, L., Marchitto,
 555 L., Benlarbi, M., Chatterjee, D., Nayrac, M., et al. (2022). Strong humoral immune responses
 556 against SARS-CoV-2 Spike after BNT162b2 mRNA vaccination with a 16-week interval
 557 between doses. Cell Host Microbe *30*, 97-109.e5. 10.1016/j.chom.2021.12.004.
- 558 29. Prévost, J., Gasser, R., Beaudoin-Bussières, G., Richard, J., Duerr, R., Laumaea, A., Anand, 559 S.P., Goyette, G., Benlarbi, M., Ding, S., et al. (2020). Cross-Sectional Evaluation of Humoral 560 Responses against SARS-CoV-2 Cell Rep. Med. 100126. Spike. 1, 561 10.1016/j.xcrm.2020.100126.
- 30. Anand, S.P., Prévost, J., Nayrac, M., Beaudoin-Bussières, G., Benlarbi, M., Gasser, R.,
 Brassard, N., Laumaea, A., Gong, S.Y., Bourassa, C., et al. (2021). Longitudinal analysis of
 humoral immunity against SARS-CoV-2 Spike in convalescent individuals up to eight months
 post-symptom onset. Cell Rep. Med., 100290. 10.1016/j.xcrm.2021.100290.
- 31. Tauzin, A., Gendron-Lepage, G., Nayrac, M., Anand, S.P., Bourassa, C., Medjahed, H.,
 Goyette, G., Dubé, M., Bazin, R., Kaufmann, D.E., et al. (2022). Evolution of Anti-RBD IgG
 Avidity Following SARS-CoV-2 Infection. Viruses *14*, 532. 10.3390/v14030532.
- 32. Nayrac, M., Dubé, M., Sannier, G., Nicolas, A., Marchitto, L., Tastet, O., Tauzin, A., Brassard,
 N., Lima-Barbosa, R., Beaudoin-Bussières, G., et al. (2022). Temporal associations of B and
 T cell immunity with robust vaccine responsiveness in a 16-week interval BNT162b2 regimen.
 Cell Rep. 0. 10.1016/j.celrep.2022.111013.

- 33. Li, W., Chen, Y., Prévost, J., Ullah, I., Lu, M., Gong, S.Y., Tauzin, A., Gasser, R., Vézina, D.,
 Anand, S.P., et al. (2022). Structural basis and mode of action for two broadly neutralizing
 antibodies against SARS-CoV-2 emerging variants of concern. Cell Rep. *38*, 110210.
 10.1016/j.celrep.2021.110210.
- 577 34. Prévost, J., Richard, J., Gasser, R., Ding, S., Fage, C., Anand, S.P., Adam, D., Vergara, N.G.,
 578 Tauzin, A., Benlarbi, M., et al. (2021). Impact of temperature on the affinity of SARS-CoV-2
 579 Spike glycoprotein for host ACE2. J. Biol. Chem., 101151. 10.1016/j.jbc.2021.101151.
- 35. Ullah, I., Prévost, J., Ladinsky, M.S., Stone, H., Lu, M., Anand, S.P., Beaudoin-Bussières, G.,
 Symmes, K., Benlarbi, M., Ding, S., et al. (2021). Live imaging of SARS-CoV-2 infection in
 mice reveals that neutralizing antibodies require Fc function for optimal efficacy. Immunity,
 S1074-7613(21)00347-2. 10.1016/j.immuni.2021.08.015.
- 36. Gruell, H., Vanshylla, K., Tober-Lau, P., Hillus, D., Schommers, P., Lehmann, C., Kurth, F.,
 Sander, L.E., and Klein, F. (2022). mRNA booster immunization elicits potent neutralizing
 serum activity against the SARS-CoV-2 Omicron variant. Nat. Med., 1–4. 10.1038/s41591021-01676-0.
- 37. Garrett, N., Tapley, A., Andriesen, J., Seocharan, I., Fisher, L.H., Bunts, L., Espy, N., Wallis,
 C.L., Randhawa, A.K., Ketter, N., et al. (2022). High Rate of Asymptomatic Carriage
 Associated with Variant Strain Omicron. medRxiv, 2021.12.20.21268130.
 10.1101/2021.12.20.21268130.
- 38. Sun, K., Tempia, S., Kleynhans, J., von Gottberg, A., McMorrow, M.L., Wolter, N., Bhiman,
 J.N., Moyes, J., du Plessis, M., Carrim, M., et al. (2022). SARS-CoV-2 transmission,
 persistence of immunity, and estimates of Omicron's impact in South African population
 cohorts. Sci. Transl. Med. *0*, eabo7081. 10.1126/scitranslmed.abo7081.
- 39. Altarawneh, H.N., Chemaitelly, H., Ayoub, H.H., Hasan, M.R., Coyle, P., Yassine, H.M., AlKhatib, H.A., Benslimane, F.M., Al-Kanaani, Z., Al-Kuwari, E., et al. (2022). Protection of
 SARS-CoV-2 natural infection against reinfection with the Omicron BA.4 or BA.5 subvariants.
 2022.07.11.22277448. 10.1101/2022.07.11.22277448.
- 600 40. Carazo, S., Skowronski, D.M., Brisson, M., Sauvageau, C., Brousseau, N., Gilca, R., Ouakki,
 601 M., Barkati, S., Fafard, J., Talbot, D., et al. (2022). Protection against Omicron re-infection
 602 conferred by prior heterologous SARS-CoV-2 infection, with and without mRNA vaccination.
 603 2022.04.29.22274455. 10.1101/2022.04.29.22274455.
- 41. Goel, R.R., Apostolidis, S.A., Painter, M.M., Mathew, D., Pattekar, A., Kuthuru, O., Gouma,
 S., Hicks, P., Meng, W., Rosenfeld, A.M., et al. (2021). Distinct antibody and memory B cell
 responses in SARS-CoV-2 naïve and recovered individuals following mRNA vaccination. Sci.
 Immunol. 6. 10.1126/sciimmunol.abi6950.
- 42. Valcourt, E.J., Manguiat, K., Robinson, A., Lin, Y.-C., Abe, K.T., Mubareka, S., Shigayeva,
 A., Zhong, Z., Girardin, R.C., DuPuis, A., et al. (2021). Evaluating Humoral Immunity against
 SARS-CoV-2: Validation of a Plaque-Reduction Neutralization Test and a Multilaboratory
 Comparison of Conventional and Surrogate Neutralization Assays. Microbiol. Spectr. *9*,
 e0088621. 10.1128/Spectrum.00886-21.

- 43. Sun, H., Xu, J., Zhang, G., Han, J., Hao, M., Chen, Z., Fang, T., Chi, X., and Yu, C. (2022).
 Developing Pseudovirus-Based Neutralization Assay against Omicron-Included SARS-CoV2 Variants. Viruses *14*, 1332. 10.3390/v14061332.
- 44. Wang, Z., Muecksch, F., Muenn, F., Cho, A., Zong, S., Raspe, R., Ramos, V., Johnson, B.,
 Ben Tanfous, T., DaSilva, J., et al. (2022). Humoral immunity to SARS-CoV-2 elicited by
 combination COVID-19 vaccination regimens. J. Exp. Med. 219, e20220826.
 10.1084/jem.20220826.
- 45. Schmidt, F., Muecksch, F., Weisblum, Y., Da Silva, J., Bednarski, E., Cho, A., Wang, Z.,
 Gaebler, C., Caskey, M., Nussenzweig, M.C., et al. (2022). Plasma Neutralization of the
 SARS-CoV-2 Omicron Variant. N. Engl. J. Med. *386*, 599–601. 10.1056/NEJMc2119641.
- 46. Robbiani, D.F., Gaebler, C., Muecksch, F., Lorenzi, J.C.C., Wang, Z., Cho, A., Agudelo, M.,
 Barnes, C.O., Gazumyan, A., Finkin, S., et al. (2020). Convergent antibody responses to
 SARS-CoV-2 in convalescent individuals. Nature *584*, 437–442. 10.1038/s41586-020-24569.
- 47. Jennewein, M.F., MacCamy, A.J., Akins, N.R., Feng, J., Homad, L.J., Hurlburt, N.K.,
 Seydoux, E., Wan, Y.-H., Stuart, A.B., Edara, V.V., et al. (2021). Isolation and characterization
 of cross-neutralizing coronavirus antibodies from COVID-19+ subjects. Cell Rep. *36*, 109353.
 10.1016/j.celrep.2021.109353.
- 48. Gong, S.Y., Chatterjee, D., Richard, J., Prévost, J., Tauzin, A., Gasser, R., Bo, Y., Vézina,
 D., Goyette, G., Gendron-Lepage, G., et al. (2021). Contribution of single mutations to
 selected SARS-CoV-2 emerging variants spike antigenicity. Virology *563*, 134–145.
 10.1016/j.virol.2021.09.001.
- 49. Tauzin, A., Gong, S.Y., Beaudoin-Bussières, G., Vézina, D., Gasser, R., Nault, L., Marchitto,
 L., Benlarbi, M., Chatterjee, D., Nayrac, M., et al. (2022). Strong humoral immune responses
 against SARS-CoV-2 Spike after BNT162b2 mRNA vaccination with a 16-week interval
 between doses. Cell Host Microbe *30*, 97-109.e5. 10.1016/j.chom.2021.12.004.
- 50. Beaudoin-Bussières, G., Laumaea, A., Anand, S.P., Prévost, J., Gasser, R., Goyette, G.,
 Medjahed, H., Perreault, J., Tremblay, T., Lewin, A., et al. (2020). Decline of Humoral
 Responses against SARS-CoV-2 Spike in Convalescent Individuals. mBio *11*.
 10.1128/mBio.02590-20.
- 51. Ding, S., Laumaea, A., Benlarbi, M., Beaudoin-Bussières, G., Gasser, R., Medjahed, H.,
 Pancera, M., Stamatatos, L., McGuire, A.T., Bazin, R., et al. (2020). Antibody Binding to
 SARS-CoV-2 S Glycoprotein Correlates with but Does Not Predict Neutralization. Viruses *12*,
 1214. 10.3390/v12111214.



Figure 1

















4 Months



Figure 2

















4 Months



Table S1. Flow cytometry antibody staining panel for B cells characterization. Related to Figure 1 and the STAR Methods section.

Marker-Fluorophore	Clone	Vendor	Catalog #
CD3 – BV480	UCHT1	BD Biosciences	566105
CD14 – BV480	M5E2	BD Biosciences	746304
CD16 – BV480	3G8	BD Biosciences	566108
CD19 – BV650	SJ25C1	Biolegend	363026
CD20 – BV711	2H7	Biolegend	302342
CD21 – BV786	B-LY4	BD Biosciences	740969
CD24 – BUV805	ML5	BD Biosciences	742010
CD27 – APC-R700	M-T271	BD Biosciences	565116
CD38 – BB790	HIT2	BD Biosciences	CUSTOM
CD56 – BV480	NCAM16.2	BD Biosciences	566124
CD138 – BUV661	MI15	BD Biosciences	749873
CCR10 – BUV395	1B5	BD Biosciences	565322
HLA-DR – BB700	G46-6	BD Biosciences	566480
lgA - PE	IS11-8E10	Miltenyi Biotec	130-113-476
lgD – BUV563	IA6-2	BD Biosciences	741394
lgG – BV421	G18-147	BD Biosciences	562581
IgM – BUV737	UCH-B1	BD Biosciences	748928
LIVE/DEAD Fixable dead cell	N/A	Thermo Fisher Scientific	L34960



Figure S1. Gating strategy for SARS-CoV-2-specific B cell characterization and SARS-CoV-2 Spikes recognition, Related to Figures 1 and 2. (**A**) Representative flow cytometry gates to identify RBD-specific B cells. (**B**) Representative flow cytometry gates to identify the level of recognition of the Spikes. 293T cells were transfected with the full-length Spike from different SARS-CoV-2 variants (D614G, BA.2, BA.4/5, BA.2.75, BA.4.6 and BQ.1.1), stained with plasma or the CV3-25 mAb and analyzed by flow cytometry. Cells expressing the Spike were identified according to cell morphology by light-scatter parameters (first column) and excluding doublets cells (second column). Cells were then gated on living cells (excluding the dead cells labeled with Aqua vivid; third column). Finally, the percentage of GFP+ cells was used to measure the median of fluorescence of Alexa Fluor 647+ cells (last column).





Figure S2. Recognition and infectivity of different Omicron subvariant Spikes, Related to Figures 2 and 3.

Α

(A) Mutations and deletions in the Spike amino acid sequence from D614G and Omicron subvariants compared to the ancestral strain. NTD: N-terminal domain; RBD: receptor-binding domain; RBM : receptor-binding motif; SD2: subdomain 2; S2: subunit 2. (B) 293T cells were transfected with the full-length Spike from different SARS-CoV-2 variants (D614G, BA.2, BA.4/5, BA.2.75, BA.4.6 and BQ.1.1), stained with the CV3-25 mAb and analyzed by flow cytometry. (C) VSV-G-pseudotyped viral particles expressing the indicated SARS-CoV-2 S glycoprotein were added to plates coated with CV3-25. Free virions were washed away, and Cf2Th cells were added to the wells. After 48 hours, cells were lysed, and the luciferase activity was measured. Luciferase signals were normalized to those obtained with the CV3-25 mAb. (D) Pseudoviral particles bearing the indicated SARS-CoV-2 S were used to infect 293T-ACE2 cells for 2 days at 37°C. RLU values obtained were normalized to D614G. (C-D) The experiments were repeated three times. Error bars indicate means \pm SEM.